1. Diagnostic and vaccine potential of Zika virus envelope protein (E) derivates produced in bacterial and insect cells. Lunardelli VAS, Almeida BDS, Apostolico JS, Rezende T, Yamamoto MM, Pereira SS, Bueno MFC, Pereira LR, Carvalho KI, Slhessarenko RD, de Souza Ferreira LC, Boscardin SB, Rosa DS. Front Immunol. 2023 Mar 16;14:1071041. doi: 10.3389/fimmu.2023.1071041. eCollection 2023.
2. Establishment of an Antiplasmodial Vaccine Based on PfRH5-Encoding RNA Replicons Stabilized by Cationic Liposomes. Fotoran WL, Silva JRD, Glitz C, Ferreira LCS, Wunderlich G. Pharmaceutics. 2023 Apr 12;15(4):1223. doi: 10.3390/pharmaceutics15041223.
3. The third vaccine dose significantly reduces susceptibility to the B.1.1.529 (Omicron) SARS-CoV-2 variant. Farias JP, Pinheiro JR, Andreata-Santos R, Fogaça MMC, da Silva Brito RD, da Cruz EF, de Castro-Amarante MF, Pereira SS, Dos Santos Almeida S, Moreira LM, da Conceição Simões R, Luiz WB, Birbrair A, Belmok A, Ribeiro BM, Maricato JT, Braconi CT, de Souza Ferreira LC, Janini LMR, Amorim JH. J Med Virol. 2023 Feb;95(2):e28481. doi: 10.1002/jmv.28481.PMID: 36609686
4. Single immunizations of self-amplifying or non-replicating mRNA-LNP vaccines control HPV-associated tumors in mice. Ramos da Silva J, Bitencourt Rodrigues K, Formoso Pelegrin G, Silva Sales N, Muramatsu H, de Oliveira Silva M, Porchia BFMM, Moreno ACR, Aps LRMM, Venceslau-Carvalho AA, Tombácz I, Fotoran WL, Karikó K, Lin PJC, Tam YK, de Oliveira Diniz M, Pardi N, de Souza Ferreira LC. Sci Transl Med. 2023 Mar 8;15(686):eabn3464. doi: 10.1126/scitranslmed.abn3464. Epub 2023 Mar 8.
5. The Anti-Dengue Virus Peptide DV2 Inhibits Zika Virus Both In Vitro and In Vivo. Castro-Amarante MF, Pereira SS, Pereira LR, Santos LS, Venceslau-Carvalho AA, Martins EG, Balan A, Souza Ferreira LC. Viruses. 2023 Mar 25;15(4):839. doi: 10.3390/v15040839.
6. Editorial: Emerging human viruses with pandemic potential: Diagnostics, pathogenesis, and therapeutics.Botosso VF, Durigon EL, de Souza EE. Front Cell Infect Microbiol. 2023 Mar 23;13:1182522. doi: 10.3389/fcimb.2023.1182522. eCollection 2023.
7. Identification of Zika Virus NS1-Derived Peptides with Potential Applications in Serological Tests. Prudencio CR, Gomes da Costa V, Rocha LB, Costa HHM, Orts DJB, da Silva Santos FR, Rahal P, Lino NAB, da Conceição PJP, Bittar C, Machado RRG, Durigon EL, Araujo JP Jr, Polatto JM, da Silva MA, de Oliveira JA, Mitsunari T, Pereira LR, Andreata-Santos R, de Souza Ferreira LC, Luz D, Piazza RMF. Viruses. 2023 Feb 28;15(3):654. doi: 10.3390/v15030654.
8. Dermatological Manifestations in COVID-19: A Case Study of SARS-CoV-2 Infection in a Genetic Thrombophilic Patient with Mthfr Mutation. Celestino GG, Amarante MK, Vespero EC, Tavares ER, Yamauchi LM, Candido ÉD, de Oliveira DBL, Durigon EL, Yamada-Ogatta SF, Faccin-Galhardi LC. Pathogens. 2023 Mar 10;12(3):438. doi: 10.3390/pathogens12030438.
9. Assessment of the Interferon-Lambda-3 Polymorphism in the Antibody Response to COVID-19 in Older Adults Seropositive for CMV. Nardy A, Camargo CTS, Oliveira YFC, Silva FCD, Almeida MS, Monteiro FR, Silva BR, Amaral JBD, Oliveira DBL, Durigon EL, Scagion GP, Chalup VN, Candido ÉD, Aguiar AS, Novo NF, Shio MT, França CN, Nali LHDS, Bachi ALL. Vaccines (Basel). 2023 Feb 18;11(2):480. doi: 10.3390/vaccines11020480.
10. Older Adults Who Maintained a Regular Physical Exercise Routine before the Pandemic Show Better Immune Response to Vaccination for COVID-19. Silva BR, Monteiro FR, Cezário K, Amaral JBD, Paixão V, Almeida EB, Santos CAFD, Amirato GR, Oliveira DBL, Durigon EL, Aguiar AS, Vieira RP, Santos JMBD, Furtado GE, França CN, Shio MT, Bachi ALL. Int J Environ Res Public Health. 2023 Jan 20;20(3):1939. doi: 10.3390/ijerph20031939.
11. Clinical markers of post-Chikungunya chronic inflammatory joint disease: A Brazilian cohort. Lázari CDS, Ramundo MS, Ten-Caten F, Bressan CS, de Filippis AMB, Manuli ER, de Moraes I, Pereira GM, Côrtes MF, Candido DDS, Gerber AL, Guimarães AP, Faria NR, Nakaya HI, Vasconcelos ATR, Brasil P, Paranhos-Baccalà G, Sabino EC. PLoS Negl Trop Dis. 2023 Jan 6;17(1):e0011037. doi: 10.1371/journal.pntd.0011037. eCollection 2023 Jan.
12. Comparative transcriptomic analysis of long noncoding RNAs in Leishmania-infected human macrophages. Fernandes JCR, Gonçalves ANA, Floeter-Winter LM, Nakaya HI, Muxel SM. Front Genet. 2023 Jan 4;13:1051568. doi: 10.3389/fgene.2022.1051568. eCollection 2022.
13. Immunodominant antibody responses directed to SARS-CoV-2 hotspot mutation sites and risk of immune escape. Oliveira JR, Ruiz CMR, Machado RRG, Magawa JY, Daher IP, Urbanski AH, Schmitz GJH, Arcuri HA, Ferreira MA, Sasahara GL, de Medeiros GX, Júnior RCVS, Durigon EL, Boscardin SB, Rosa DS, Schechtman D, Nakaya HI, Cunha-Neto E, Gadermaier G, Kalil J, Coelho V, Santos KS. Front Immunol. 2023 Jan 5;13:1010105. doi: 10.3389/fimmu.2022.1010105. eCollection 2022.
14. Electrochemical magneto-immunoassay for detection of zika virus antibody in human serum. CASTRO, KARLA R.; SETTI, GRAZIELLE O.; DE OLIVEIRA, TÁSSIA R.; RODRIGUES-JESUS, MÔNICA J.; BOTOSSO, VIVIANE F.; PERINI DE ARAUJO, ANA P.; DURIGON, EDSON L.; FERREIRA, LUÍS C.S.; FARIA, RONALDO C. (2023). TALANTA, 256:124277. (doi:10.1016/j.talanta.2023.124277).
15. Recombinant Proteins for Assembling as Nano- and Micro-Scale Materials for Drug Delivery: A Host Comparative Overview. CORCHERO, JOSÉ LUIS ; FAVARO, MARIANNA T. P. ; MÁRQUEZ-MARTÍNEZ, MERCE ; LASCORZ, JARA ; MARTÍNEZ-TORRÓ, CARLOS ; SÁNCHEZ, JULIETA M. ; LÓPEZ-LAGUNA, HÈCTOR ; DE SOUZA FERREIRA, LUÍS CARLOS ; VÁZQUEZ, ESTHER ; FERRER-MIRALLES, NEUS ; VILLAVERDE, ANTONIO ; PARLADÉ, ELOI (2023). Pharmaceutics, 15: 1197. (doi: 10.3390/ pharmaceutics15041197).
16. Multi-epitope Antigen for Specific Serological Detection of Dengue Viruses. PEREIRA, S. S., R. ANDREATA-SANTOS, M.F. CASTRO-AMARANTE, A.A. VENCESLAU-CARVALHO, N.S. SALES, M.O. SILVA, R.P.S. ALVES, P. JUNGMANN AND L.C.S. FERREIRA. (2023) Viruses, 15:1936. (doi:10.3390/v15091936).
17. The fourth COVID-19 vaccine dose increased the neutralizing antibody response against the SARS-CoV-2 Omicron (B.1.1.529) variant in a diverse Brazilian population. FARIAS, J. P., R. ANDREATA-SANTOS, R. D. DA SILVA BRITO, M. S. SOUZA, M. M. C. FOGAÇA, J. R. PINHEIRO, E. F. DA CRUZ, W. LIANG, R. C. SIMÕES, W. B. LUIZ, A. BIRBRAIR, P. O. VIDAL, J. T. MARICATO, C. T. BRACONI, L. C. S. FERREIRA, L. M. R. JANINI, AND J. H. AMORIM. (2023) Microbiology Spectrum, 11(6):e0285723 (doi.org/ 10.1128/spectrum.02857).
18. SARS-CoV 2 Nanovaccine Composed of Microfluidic-Produced Gold Nanoparticles Induces Neutralizing Immune Responses. DALIBERA, N. C., M. J. RODRIGUES-JESUS, R. ANDREATA-SANTOS, L. M. R. JANINI, A. F. OLIVEIRA, A. R. AZZONI, L. C. S. FERREIRA, AND M.T. P. FAVARO (2023). ACS Appl. Nano Mater., 6: 22774-22783. (doi.org/10.1021/acsanm.3c03905).
19. SARS-CoV-2 Spike protein peptides displayed in the Pyrococcus furiosus RAD system preserve epitopes antigenicity, immunogenicity, and virus-neutralizing activity of antibodies. Victor Bolsanelli Cioffi, Maria Fernanda de Castro-Amarante, Aleksei Lulla, Robert Andreata-Santos, Mario Costa Cruz, Ana Carolina Ramos Moreno, Mariângela de Oliveira Silva, Bianca de Miranda Peres, Lucio Holanda Gondim de Freitas Junior, Carolina Borsoi Moraes, Edison Luiz Durigon, Nicola Coker Gordon, Marko Hyvönen, Luís Carlos de Souza Ferreira, Andrea Balan. Scientific Reports, 2023 Oct 5;13(1):16821. doi: 10.1038/s41598-023-43720-8.